Previous 10 | Next 10 |
Tiziana Life Sciences PLC (NASDAQ: TLSA ) +68% on inhalable treatment for COVID-19. More news on: Tiziana Life Sciences PLC, Nautilus, Inc., Exantas Capital Corp., Stocks on the move, , Read more ...
Thinly traded nano cap CNS Pharmaceuticals (NASDAQ: CNSP ) jumps 19% premarket on light volume on the heels of its announced collaboration with WPD Pharmaceuticals to develop several preclinical COVID-19 candidates, including WP112, that WPD in-licensed from Moleculin Biotech (...
VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company , is pleased to announce that independent research on its WP1122 drug compound ...
Gainers: Moleculin Biotech (NASDAQ: MBRX ) +121% . More news on: Moleculin Biotech, Inc., Ellington Financial Inc., Intelsat S.A., Stocks on the move, , Read more ...
VANCOUVER, British Columbia, March 24, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD” ) a clinical stage pharmaceutical company , announces it has entered into a development agreement (the “ Agreement...
March 23, 2020 Palm Beach, FL – March 23, 2020 – In the months since the global public health crisis rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic. The crisis has catalyzed ...
HOUSTON , March 23, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company primarily specializing in the development of novel treatments for cancers of the brain and central nervous system, announces it has entered into a...
CNS Pharmaceuticals, Inc. (CNSP) Q4 2019 Earnings Conference Call March 12, 2020 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations John Climaco - Chief Executive Officer Chris Downs - Chief Financial Officer Conference Call Participants Presentation ...
CNS Pharmaceuticals (NASDAQ: CNSP ): Q4 GAAP EPS of -$0.17 misses by $0.14 . Cash and equivalents of $7.2M Press Release More news on: CNS Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
HOUSTON , March 12, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced bu...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NASDAQ Market:
CNS Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Agape ATP Corporation (ATPC) rose 148.2% to $0.2172 on volume of 69,599,062 shares Imunon Inc. (IMNN) rose 154.6% to $3.03 on volume of 68,427,736 shares Jet.AI Inc. (JTAI) rose 27.2% to $0.380102 on volume of 41,454,602 shares SoFi T...
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to changing the treatment paradigm in GBM Drug candidate, TPI 287, awarded Orphan designation and studied in over 350 patients to date...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in next month’s 2024 SNO/ASCO CNS Cancer Conference. The event will be held...